Rishi Rajesh, Agnes Anna Mooslechner, Hannah Schweighofer, Svetlana Pahernik, Ilse Lanz, Reham Atallah, Wolfgang Platzer, Clemens Aigner, Alberto Benazzo, Stefano Angiari, Leigh Marsh, Grazyna Kwapiszewska, Akos Heinemann, Thomas Bärnthaler
{"title":"Succinate aggravates pulmonary fibrosis through the succinate/SUCNR1 axis.","authors":"Rishi Rajesh, Agnes Anna Mooslechner, Hannah Schweighofer, Svetlana Pahernik, Ilse Lanz, Reham Atallah, Wolfgang Platzer, Clemens Aigner, Alberto Benazzo, Stefano Angiari, Leigh Marsh, Grazyna Kwapiszewska, Akos Heinemann, Thomas Bärnthaler","doi":"10.1152/ajplung.00286.2024","DOIUrl":null,"url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease that leads to destruction of alveoli and replacement by fibrotic tissue. Metabolic profiling of lung tissue and serum from patients with IPF has revealed that levels of tricarboxylic acid cycle metabolites such as succinate are altered in patients with IPF. In our study, we aim to evaluate the role of succinate and its receptor-succinate receptor 1 (SUCNR1) in the pathogenesis of lung fibrosis, with a focus on fibroblasts, a central cell in IPF. SUCNR1 expression was investigated by using Western blots, qPCR, and in situ hybridisation. In vitro assays with IPF and normal human lung fibroblasts (NHLF) were used to evaluate the effect of succinate treatment on the expression of fibrotic markers, fibroblast-myofibroblast transition, apoptosis, and signaling mechanisms. Studies with the bleomycin mouse model of pulmonary fibrosis were used to evaluate the effect of succinate in vivo. Several cell types in the lung express SUCNR1 including alveolar type II cells, fibroblasts, and macrophages. In IPF patient fibroblasts, succinate treatment increased the expression of fibrosis-associated markers, such as alpha-smooth muscle actin and collagen. Moreover, succinate exaggerated transforming growth factor-beta (TGF-β)-mediated fibroblast-to-myofibroblast transition in NHLF. In vivo, succinate treatment significantly increased collagen accumulation in the lung and enhanced weight loss in bleomycin-treated mice. Importantly, succinate-mediated elevation of fibrosis-associated markers was lost upon knockdown of SUCNR1 or inhibition of ERK activation in IPF patient-derived fibroblasts. Succinate exerted profibrotic effects in vitro and in vivo. Thus, SUCNR1 antagonism may be a potential therapeutic target for the treatment of IPF.<b>NEW & NOTEWORTHY</b> This paper highlights the role of the succinate/SUCNR1 axis in pulmonary fibrosis. Receptor activation leads to profibrotic changes in IPF patient-derived fibroblasts. This finding could also be replicated in a mouse model of pulmonary fibrosis.</p>","PeriodicalId":7593,"journal":{"name":"American journal of physiology. Lung cellular and molecular physiology","volume":" ","pages":"L671-L684"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617945/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of physiology. Lung cellular and molecular physiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1152/ajplung.00286.2024","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease that leads to destruction of alveoli and replacement by fibrotic tissue. Metabolic profiling of lung tissue and serum from patients with IPF has revealed that levels of tricarboxylic acid cycle metabolites such as succinate are altered in patients with IPF. In our study, we aim to evaluate the role of succinate and its receptor-succinate receptor 1 (SUCNR1) in the pathogenesis of lung fibrosis, with a focus on fibroblasts, a central cell in IPF. SUCNR1 expression was investigated by using Western blots, qPCR, and in situ hybridisation. In vitro assays with IPF and normal human lung fibroblasts (NHLF) were used to evaluate the effect of succinate treatment on the expression of fibrotic markers, fibroblast-myofibroblast transition, apoptosis, and signaling mechanisms. Studies with the bleomycin mouse model of pulmonary fibrosis were used to evaluate the effect of succinate in vivo. Several cell types in the lung express SUCNR1 including alveolar type II cells, fibroblasts, and macrophages. In IPF patient fibroblasts, succinate treatment increased the expression of fibrosis-associated markers, such as alpha-smooth muscle actin and collagen. Moreover, succinate exaggerated transforming growth factor-beta (TGF-β)-mediated fibroblast-to-myofibroblast transition in NHLF. In vivo, succinate treatment significantly increased collagen accumulation in the lung and enhanced weight loss in bleomycin-treated mice. Importantly, succinate-mediated elevation of fibrosis-associated markers was lost upon knockdown of SUCNR1 or inhibition of ERK activation in IPF patient-derived fibroblasts. Succinate exerted profibrotic effects in vitro and in vivo. Thus, SUCNR1 antagonism may be a potential therapeutic target for the treatment of IPF.NEW & NOTEWORTHY This paper highlights the role of the succinate/SUCNR1 axis in pulmonary fibrosis. Receptor activation leads to profibrotic changes in IPF patient-derived fibroblasts. This finding could also be replicated in a mouse model of pulmonary fibrosis.
期刊介绍:
The American Journal of Physiology-Lung Cellular and Molecular Physiology publishes original research covering the broad scope of molecular, cellular, and integrative aspects of normal and abnormal function of cells and components of the respiratory system. Areas of interest include conducting airways, pulmonary circulation, lung endothelial and epithelial cells, the pleura, neuroendocrine and immunologic cells in the lung, neural cells involved in control of breathing, and cells of the diaphragm and thoracic muscles. The processes to be covered in the Journal include gas-exchange, metabolic control at the cellular level, intracellular signaling, gene expression, genomics, macromolecules and their turnover, cell-cell and cell-matrix interactions, cell motility, secretory mechanisms, membrane function, surfactant, matrix components, mucus and lining materials, lung defenses, macrophage function, transport of salt, water and protein, development and differentiation of the respiratory system, and response to the environment.